Groundbreaking research unveiled at the recent European Congress on Obesity (ECO) 2026 in Istanbul sheds new light on the phenomenon known as ‘food noise’ and its modulation through pharmacological intervention combined with behavioral strategies. Dr. Hanim Diktas from Louisiana State University’s Pennington Biomedical Research Center presented pioneering findings illustrating how the addition of GLP-1 receptor agonists to standard behavioral weight management programs significantly attenuates intrusive food-related thoughts, a psychological barrier often undermining dietary adherence and successful weight loss.
‘Food noise’—a term gaining traction in obesity research—refers to persistent and disruptive cognitive preoccupation with food, manifesting as uncontrollable, negative, and distracting thoughts that impede healthy eating behaviors. Although anecdotal evidence suggested that GLP-1 receptor agonists, a class of drugs initially developed for glycemic control in diabetes management, show promise in reducing these maladaptive food-related cognitions, this study provided critical empirical validation by quantitatively measuring changes in food noise under real-world conditions.
In this observational cohort, 417 adult participants engaged in a digital behavioral weight management platform modeled after Weight Watchers programs. The cohort was stratified into two groups: those initiating GLP-1 receptor agonists adjunctively with behavioral therapy (Weight Watchers Med+) and those receiving behavioral therapy alone without GLP-1 RA use (Weight Watchers Core+). Notably, individuals already on any weight loss pharmacotherapy at baseline were excluded to ensure the purity of treatment effects.
The core investigation utilized the Food Noise Questionnaire (FNQ), a rigorously validated psychometric tool assessing cognitive intrusions related to food via five targeted, Likert-scale items. Each item rates the frequency and intensity of food-related thoughts that are constant, uncontrollable, excessive, negatively impactful, and distracting. Scores range from zero to 20, encapsulating the severity of an individual’s food noise experience. Participants completed the FNQ at baseline and one month later, aligning with digitally recorded body weight measurements.
Initial FNQ assessments revealed higher baseline food noise in the GLP-1 RA group, averaging scores of 13.1 compared to 10.7 in the control group. After one month, the Med+ group exhibited a pronounced mean FNQ reduction to 8.7—a decrease reflecting a significant alleviation in intrusive food thoughts. Conversely, the Core+ group showed a more modest reduction, dropping to 9.7. Crucially, statistical models accounting for baseline differences confirmed a robust effect of GLP-1 receptor agonist therapy on diminishing food noise, highlighting a mean adjusted decrease three points greater than behavioral therapy alone.
Importantly, this attenuation of food noise occurred concomitantly with behavioral interventions, underscoring a synergistic interplay between pharmacologic appetite regulation and cognitive-behavioral strategies. This neuropsychological shift may represent an early mechanistic indicator for the efficacy of weight management regimes incorporating GLP-1 receptor agonists, beyond mere caloric restriction and counseling sessions.
Ongoing analyses aim to dissect the correlation between weight changes and improvements in food noise metrics, potentially elucidating causal pathways linking neurochemical modulation to behavioral outcomes. Understanding whether reduced food noise leads to sustained weight loss or improved metabolic parameters will be pivotal for clinical translation and personalized treatment algorithms.
The implications of these findings extend deeply into obesity medicine and behavioral neuroscience. Persistent food thoughts have long been recognized as obstacles to dietary self-regulation, often culminating in relapse and weight regain. GLP-1 receptor agonists appear to directly modulate central nervous system circuits governing appetite, reward processing, and cognitive control, thereby dampening cognitive interference—phenomenologically captured as food noise—which in turn may facilitate improved adherence to nutritional recommendations.
Further research is warranted to explore the temporal dynamics of food noise reduction over extended treatment periods. Longitudinal investigations could reveal whether these cognitive benefits are sustained or if compensatory neuroadaptations diminish efficacy. Additionally, dissecting the neurobiological substrates influenced by GLP-1 receptor agonists could identify novel targets for obesity therapies that more effectively integrate pharmacologic and psychological aspects.
The research team, anchored at the Pennington Biomedical Research Center—a hub for metabolic and obesity science—has set a precedent integrating quantified patient-reported cognitive measures within large-scale behavioral health interventions. Their innovative use of the FNQ demonstrates the importance of subjective psychological constructs in the context of objective therapeutic outcomes, bridging a gap traditionally overlooked in weight management trials.
It is noteworthy that the study sample predominantly comprised older, white females with an average BMI in the mid-thirties, a demographic characteristic that may influence generalizability. Future randomized controlled trials with diversified cohorts will be essential to confirm these preliminary but promising results across different populations, including varying ages, ethnicities, and comorbid conditions.
The confluence of behavioral science, pharmacotherapy, and digital health platforms exemplified in this work marks a paradigm shift in tackling obesity, a multifactorial disease requiring multifaceted interventions. By illuminating a measurable psychological marker—food noise—and demonstrating its modulation, this research paves the way for more nuanced, integrative therapeutic frameworks.
As obesity prevalence escalates globally, the development and validation of tools like the Food Noise Questionnaire offer clinicians and researchers tangible means to quantify subjective cognitive states, personalize interventions, and potentially predict patient responsiveness to weight loss therapies incorporating GLP-1 receptor agonists. Ultimately, such advancements promise to enhance treatment adherence, efficacy, and patients’ quality of life.
For further details on this innovative metric, the Food Noise Questionnaire and its translations are accessible through the Pennington Biomedical Research Center’s dedicated portal. The ongoing commitment of this institution to tackling obesity through collaborative, multidisciplinary research continues to propel the field toward breakthroughs with meaningful real-world impact.
Subject of Research: People
Article Title: Changes in Food Noise in Two Weight Management Programs: Effects of GLP-1 Receptor Agonists
News Publication Date: (Not specified in the source)
Web References:
Food Noise Questionnaire: www.pbrc.edu/fnq
Link to publication on FNQ: https://onlinelibrary.wiley.com/doi/10.1002/oby.24216
Image Credits: PBRC
Keywords
Body weight, Weight loss, Weight gain, Food science, Foods, Obesity, Childhood obesity, Drug research, Clinical research, Scientific facilities, Medical research facilities, Research universities
Tags: behavioral weight management programscognitive barriers to dietingcombination therapy for obesitydigital weight loss platformsfood noise in obesityGLP-1 receptor agonists for weight lossimpact of food-related thoughts on diet adherenceobesity medications and behavioral therapyobservational cohort studies in obesitypharmacological interventions for obesitypsychological aspects of weight lossWeight Watchers and obesity treatment
